1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The 2025 grant cycle is closed. Page says Blue Fund is no longer accepting applications for 2024 and asks applicants to stay tuned for the next cycle.
Blue Fund Grant Cycle (Western New York) is sponsored by Highmark Blue Cross Blue Shield. The Blue Fund, part of Highmark's Bright Blue Futures program, awards major grants to nonprofit organizations in Western New York for initiatives addressing critical health needs such as behavioral health, cardiovascular health, healthcare workforce development, and maternal hea…
Get alerted about grants like this
Save a search for “Highmark Blue Cross Blue Shield” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Highmark Blue Cross Blue Shield Blue Fund (Western NY) Highmark BCBS Blue Fund (Western NY) Highmark Blue Cross Blue Shield Blue Fund (Western NY) Highmark Blue Cross Blue Shield (Western NY) is committed to eliminating health disparities and improving the health of the communities we serve. From innovative businesses to a vibrant downtown, Western New York continues to rise to the challenge.
We see this pivotal moment as an opportunity. Blue Fund contributes to the wider strategy of our company-wide Bright Blue Futures initiative, our charitable giving and community involvement program. As an enterprise, we believe our working in partnership with communities and providers within our footprint is critical to achieve lasting positive outcomes.
The Blue Fund grant cycle is closed for submissions. Performance and reporting Blue Fund will consider grant requests that address at least one or more of the following key health focus areas: Health care workforce development Highmark Blue Cross Blue Shield (Western NY) is committed to eliminating health disparities while improving the health, wellness and resilience of families, individuals, and communities in our region.
We’re looking to partner strategically with nonprofits that are improving racial and health equity by supporting social determinants of health in under-resourced communities. Proposals for funding may include requests to support capital and/or program-related project costs. Capital campaign requests must be 75% toward the project goal.
Applicants should demonstrate how the proposal will deepen and broaden current work, by facilitating the expansion of an effective program, or creating a new program based on the success of earlier work or evidence-based best practices. Blue Fund has a two-step grant application process. Applicants must submit a brief letter of intent (LOI) using Blue Fund’s online application system in accordance with the published timeline.
Selected applicants will be invited to submit a full application. Hard copy, emailed, or PDF applications will not be accepted. Performance tracking and reporting will be required using our online system.
In order to qualify for Blue Fund grants, the proposed work must serve or be located in one or more of the following eight counties of Western New York: Allegany, Cattaraugus, Chautauqua, Erie, Genesee, Niagara, Orleans, and Wyoming. Your organization must be classified as a tax-exempt nonprofit under Section 501(c)(3) of the IRS code or an educational or government entity with tax-exempt status.
Any one organization may submit one letter of intent (LOI) maximum. Grants may provide support to eligible organizations and projects for up to two years depending on project/program design, scale, and budget. Organizations that have an active Blue Fund grant are not eligible to apply for funding during this cycle.
Funding amount and budget Minimum grant request is $100,000; maximum grant request is $300,000. Applicants may request up to 15% of the grant amount for indirect costs. Expenses incurred prior to submission of a Blue Fund application should not be included in Blue Fund project budgets; they are not eligible for payment or reimbursement.
The proposed project or program should not begin, and expenses should not be incurred, before a funding decision has been communicated by Blue Fund to the applicant. Blue Fund reserves the right to pay grants in a single installment or in multiple disbursements. Performance and reporting Grantees must have the capacity to track performance and report measurable outcome results as agreed upon by Blue Fund on a regular and timely basis.
Blue Fund reserves the right to conduct an independent evaluation of grant expenditures for up to four years. The grantee agrees to provide the information necessary to complete such an evaluation. Failure to submit requested information in a timely fashion may obligate the grantee to refund the grant.
The failure of an applicant to properly close out a grant in a timely manner will be a factor when considering new grant applications. We do not fund political campaigns, exclusively religious activities, or efforts that do not align with one or more Blue Fund focus areas.
Attendance at or sponsorship of fundraising events for organizations, annual events or festivals, and the use of grant funds for purposes not pre-approved by Blue Fund or not supported through required documentation will not be funded. Media and public announcements Blue Fund is no longer accepting applications for 2024. Stay tuned for next year's grant cycle.
Stay updated with the latest news and frequently asked questions. FAQs for grant applicants Western NY Blue Fund News Do you have more questions? We have the answers.
Find answers to some of our most frequently asked questions about Blue Fund eligibility, applying and more. If you do not see your question here, please contact us directly.
Non Discrimination Policy Electronic Data Interchange CMS’s Interoperability Rule Non Discrimination Policy Electronic Data Interchange CMS’s Interoperability Rule Network Access & Adequacy Network Access & Adequacy All references to “Highmark” in this document are references to the Highmark company that is providing the member’s health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.
Highmark Blue Cross Blue Shield and Highmark Blue Shield are Medicare Advantage HMO, PPO, and/or Part D plans with a Medicare contract. Enrollment in these plans depends on contract renewal. Highmark Wholecare offers HMO plans with a Medicare Contract.
Enrollment in these plans depends on contract renewal. Highmark Health Options Duals offers HMO plans with a Medicare Contract. Enrollment in these plans depends on contract renewal.
®Blue Cross, Blue Shield and the Cross and Shield symbols are registered service marks of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield plans.
The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life Insurance Company, Highmark Care Benefits Inc., Highmark Senior Health Company, or Gateway Health Plan, Inc. d/b/a Highmark Wholecare.
Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company, Highmark Senior Health Company, or Gateway Health Plan, Inc. d/b/a Highmark Wholecare. PA: Your plan may not cover all your health care expenses. Read your plan materials carefully to determine which health care services are covered.
For more information, call the number on the back of your member ID card or, if not a member, call 866-459-4418. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield or Highmark BCBSD Health Options Inc. d/b/a Highmark Health Options. Highmark Health Options Duals is offered by Highmark Blue Cross Blue Shield.
West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company, Highmark Senior Solutions Company, or Highmark Health Options West Virginia Inc. d/b/a Highmark Health Options and Highmark Blue Cross Blue Shield. Highmark Health Options Duals is offered by Highmark Blue Cross Blue Shield. Visit https://www.
highmarkbcbswv. com/networkaccessplan to view the Access Plan required by the Health Benefit Plan Network Access and Adequacy Act. You may also request a copy by contacting us at the number on the back of your ID card.
Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.
Based on current listing details, eligibility includes: Nonprofit organizations based in one of the eight counties of Western New York (Allegany, Cattaraugus, Chautauqua, Erie, Genesee, Niagara, Orleans, and Wyoming) with a 501(c)(3) status or an educational/government entit… Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $100,000 to $300,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.